Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Sab Biotherapeutics Inc (SABS)

Sab Biotherapeutics Inc (SABS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 189,952
  • Shares Outstanding, K 47,607
  • Annual Sales, $ 1,320 K
  • Annual Income, $ -34,110 K
  • EBIT $ -43 M
  • EBITDA $ -39 M
  • 60-Month Beta 0.58
  • Price/Sales 142.24
  • Price/Cash Flow N/A
  • Price/Book 1.14

Options Overview Details

View History
  • Implied Volatility 555.44% (+85.49%)
  • Historical Volatility 73.59%
  • IV Percentile 22%
  • IV Rank 32.22%
  • IV High 735.30% on 12/11/25
  • IV Low 469.95% on 12/18/25
  • Expected Move (DTE 27) 1.19 (29.82%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 43
  • Volume Avg (30-Day) 15
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 83
  • Open Int (30-Day) 32
  • Expected Range 2.80 to 5.18

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.16
  • Number of Estimates 3
  • High Estimate -0.15
  • Low Estimate -0.17
  • Prior Year -1.23
  • Growth Rate Est. (year over year) +86.99%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.30 +20.91%
on 12/08/25
4.19 -4.77%
on 11/28/25
+0.16 (+4.18%)
since 11/19/25
3-Month
1.85 +115.68%
on 09/30/25
4.19 -4.77%
on 11/28/25
+1.52 (+61.54%)
since 09/19/25
52-Week
1.00 +299.00%
on 04/04/25
6.60 -39.55%
on 07/21/25
+0.09 (+2.31%)
since 12/19/24

Most Recent Stories

More News
First Patient Dosed in SAB BIO’s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D

Enrollment in the SAFEGUARD trial is ongoing at multiple centers globally Company on-track to share Phase 2b data in 2H 2027 MIAMI, Dec. 18, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc....

SABSW : 0.0247 (unch)
SABS : 3.99 (+1.01%)
SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D

Phase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dose and in all cohorts, including redosed healthy volunteers Study results support the chronic dosing...

SABSW : 0.0247 (unch)
SABS : 3.99 (+1.01%)
SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management

MIAMI, Dec. 08, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:  SABS ), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes...

SABSW : 0.0247 (unch)
SABS : 3.99 (+1.01%)
SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights

Initiated registrational Phase 2b SAFEGUARD trial of SAB-142 in new-onset, Stage 3 autoimmune T1D patients Multiple SAFEGUARD trial sites activated; on-track to dose first patient by year-end ...

SABSW : 0.0247 (unch)
SABS : 3.99 (+1.01%)
SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142

MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SAb Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes...

SABSW : 0.0247 (unch)
SABS : 3.99 (+1.01%)
SAB BIO to Participate in Upcoming Investor Conferences

MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SAb Biotherapeutics, Inc. (Nasdaq:  SABS ), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for autoimmune diseases,...

SABSW : 0.0247 (unch)
SABS : 3.99 (+1.01%)
SAB BIO Highlights Data in Multiple Presentations at EASD

-As SAB initiates its Phase 2b SAFEGUARD study for SAB-142 in new-onset Stage 3 autoimmune T1D patients, EASD provided an opportunity to connect with many T1D thought leaders that will participate in the...

SABSW : 0.0247 (unch)
SABS : 3.99 (+1.01%)
SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes

MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:  SABS ), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform...

SABSW : 0.0247 (unch)
SABS : 3.99 (+1.01%)
SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates

Recently raised $175 million in oversubscribed private placement which included strategic investor Sanofi and top-tier biotech investors Strong cash position with completed financing extending operational...

SABSW : 0.0247 (unch)
SABS : 3.99 (+1.01%)
SAB BIO Announces Oversubscribed $175 Million Private Placement

Participation from strategic investor Sanofi, along with new investors RA Capital Management, Commodore Capital, Vivo Capital, Blackstone Multi-Asset Investing, Spruce Street Capital, Forge Life Science...

SABSW : 0.0247 (unch)
SABS : 3.99 (+1.01%)

Business Summary

SAB Biotherapeutics Inc. is a clinical-stage biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB Biotherapeutics Inc., formerly known as Big Cypress...

See More

Key Turning Points

3rd Resistance Point 4.29
2nd Resistance Point 4.17
1st Resistance Point 4.08
Last Price 3.99
1st Support Level 3.87
2nd Support Level 3.75
3rd Support Level 3.66

See More

52-Week High 6.60
Fibonacci 61.8% 4.46
Last Price 3.99
Fibonacci 50% 3.80
Fibonacci 38.2% 3.14
52-Week Low 1.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar